Free Trial
NASDAQ:NAMS

NewAmsterdam Pharma (NAMS) Stock Price, News & Analysis

NewAmsterdam Pharma logo
$24.10 -0.38 (-1.53%)
As of 09:41 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About NewAmsterdam Pharma Stock (NASDAQ:NAMS)

Key Stats

Today's Range
$23.81
$24.81
50-Day Range
$17.96
$25.76
52-Week Range
$14.06
$27.29
Volume
874,692 shs
Average Volume
800,993 shs
Market Capitalization
$2.71 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.55
Consensus Rating
Moderate Buy

Company Overview

NewAmsterdam Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
73rd Percentile Overall Score

NAMS MarketRank™: 

NewAmsterdam Pharma scored higher than 73% of companies evaluated by MarketBeat, and ranked 283rd out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    NewAmsterdam Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    NewAmsterdam Pharma has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about NewAmsterdam Pharma's stock forecast and price target.
  • Earnings Growth

    Earnings for NewAmsterdam Pharma are expected to decrease in the coming year, from ($1.75) to ($1.79) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of NewAmsterdam Pharma is -14.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of NewAmsterdam Pharma is -14.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    NewAmsterdam Pharma has a P/B Ratio of 3.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about NewAmsterdam Pharma's valuation and earnings.
  • Percentage of Shares Shorted

    11.51% of the float of NewAmsterdam Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    NewAmsterdam Pharma has a short interest ratio ("days to cover") of 8.4.
  • Change versus previous month

    Short interest in NewAmsterdam Pharma has recently increased by 4.36%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    NewAmsterdam Pharma does not currently pay a dividend.

  • Dividend Growth

    NewAmsterdam Pharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.51% of the float of NewAmsterdam Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    NewAmsterdam Pharma has a short interest ratio ("days to cover") of 8.4.
  • Change versus previous month

    Short interest in NewAmsterdam Pharma has recently increased by 4.36%, indicating that investor sentiment is decreasing.
  • News Sentiment

    NewAmsterdam Pharma has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 18 news articles for NewAmsterdam Pharma this week, compared to 7 articles on an average week.
  • Search Interest

    4 people have searched for NAMS on MarketBeat in the last 30 days.
  • MarketBeat Follows

    1 people have added NewAmsterdam Pharma to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, NewAmsterdam Pharma insiders have sold 2,094.76% more of their company's stock than they have bought. Specifically, they have bought $248,134.00 in company stock and sold $5,445,954.00 in company stock.

  • Percentage Held by Insiders

    20.84% of the stock of NewAmsterdam Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    89.89% of the stock of NewAmsterdam Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about NewAmsterdam Pharma's insider trading history.
Receive NAMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NewAmsterdam Pharma and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NAMS Stock News Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.tc pixel
See More Headlines

NAMS Stock Analysis - Frequently Asked Questions

NewAmsterdam Pharma's stock was trading at $25.70 at the beginning of 2025. Since then, NAMS shares have decreased by 6.8% and is now trading at $23.95.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) posted its quarterly earnings data on Wednesday, August, 6th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.37. The business earned $19.15 million during the quarter, compared to the consensus estimate of $1.44 million. NewAmsterdam Pharma had a negative net margin of 259.07% and a negative trailing twelve-month return on equity of 27.27%.

Top institutional investors of NewAmsterdam Pharma include Frazier Life Sciences Management L.P. (14.79%), Adage Capital Partners GP L.L.C. (2.68%), Jennison Associates LLC (2.62%) and Alliancebernstein L.P. (2.08%). Insiders that own company stock include Nap BV Forgrowth, James N Topper, Michael H Davidson, Johannes Jacob Piete Kastelein, Douglas F Kling, Louis G Lange, Louise Frederika Kooij and Juliette Berangere Audet.
View institutional ownership trends
.

Shares of NAMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that NewAmsterdam Pharma investors own include Nextera Energy Partners (NEP), Enterprise Products Partners (EPD), Blue Owl Capital (OBDC), Pimco Corporate & Income Opportunity Fund (PTY), PayPal (PYPL) and Ventyx Biosciences (VTYX).

Company Calendar

Last Earnings
8/06/2025
Today
8/29/2025
Next Earnings (Estimated)
11/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NAMS
CIK
1936258
Fax
N/A
Employees
4
Year Founded
N/A

Price Target and Rating

High Price Target
$52.00
Low Price Target
$27.00
Potential Upside/Downside
+73.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.62)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$241.60 million
Net Margins
-259.07%
Pretax Margin
-258.91%
Return on Equity
-27.27%
Return on Assets
-25.00%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
21.08
Quick Ratio
21.08

Sales & Book Value

Annual Sales
$45.56 million
Price / Sales
59.21
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.91 per share
Price / Book
3.47

Miscellaneous

Outstanding Shares
112,630,000
Free Float
89,156,000
Market Cap
$2.70 billion
Optionable
Optionable
Beta
-0.02
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:NAMS) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners